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Abstract 
Background. Left Ventricular Assist Devices (LVAD) are increasingly used for long-
term mechanical circulatory support and are effective in improving survival and 
quality-of-life of patient with advanced heart failure. Nonetheless, they are associated 
with significant early and late morbidity rates (including pump thrombosis, 
thromboembolic events, and pump dysfunction). These complications are at least 
partially associated with suboptimal pump positioning. Currently, we are missing tools 
to further improve the positioning of LVAD devices in a patient-specific fashion 
Methods and evaluation of the hypothesis. We hypothesized that the analysis of 
the implanted device in patients presenting selected LVAD-related complications 
through segmentation and three-dimensional reconstruction of CT scans may provide 
patient-specific information into mechanical factors contributing to pump dysfunction 
and thromboembolic events, with potential to guide preventive interventions against 
development of new complications. We also hypothesized that preoperative virtual 
implantation and computer-assisted surgery in candidates to LVAD implantation may 
help in the customization of device positioning, with potential to minimize severe 
complications. The hypothesis was evaluated in a multidisciplinary fashion (cardiac 
surgeons, biomedical engineers and biomedical images processing experts). CT 
scans of 14 LVAD recipients were reconstructed through semi-automatic 
segmentation (including the whole heart, the implanted device and the chest wall). A 
coordinate system was built to quantify the coaxiality of the LVAD apical cannula with 
the mitral annulus. Patients were stratified into Group 1 (presenting complications 
such as thromboembolic events, pump dysfunction or thrombosis) and Group 2 (no 
complications). Group 1 patients presented significantly greater average rotation of 
the apical cannula towards the interventricular septum (p=0.015), although no 
difference was observed in terms of average rotation towards the anterior or posterior 
left ventricular wall.    
Conclusions. Several patient-specific factors (including left ventricular morphology 
and chest wall conflict with the device after wound closure) may influence the 
effectiveness and safety of LVAD therapy, but they are difficultly managed through 
the current implantation techniques. We suggest that the clinical results of LVAD 
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treatment can be improved through preoperative virtual implantation and computer-
assisted surgery (in order to guide device selection, exact site of left ventricular wall 
coring site). Given these preliminary results, we are examining larger patient datasets 
in order to further test the hypothesis. Dedicated tools for virtual implantation are 
currently under development.  
 
KEY WORDS: Left Ventricular Assist Device; Computer-assisted surgery; Clinical 
outcomes 
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Introduction 
   Although heart transplantation (HTx) remains the treatment of choice for advanced 
heart failure (HF), the worsening shortage of donors worldwide represents the major 
limitation of this therapy. In such scenario, the employment of long-term mechanical 
circulatory support has gained increasing importance in the current practice. The 
current implantable continuous-flow left ventricular assist devices (LVADs), based on 
magnetically-driven rotors and external power source, and are characterized by 
improved durability and smaller size than previous pulsatile intra- or paracorporeal 
devices [1]. Generally speaking, LVADs include an inflow cannula surgically placed at 
the left ventricular (LV) apex for drainage of blood, a pump body containing the 
propelling rotor, and an outflow conduit driving the propelled blood into the ascending 
aorta (Figure 1). Power is provided by a driveline exiting the skin usually in the 
abdominal region and connected to a controller with batteries. Continuous-flow 
LVADs have been associated with a decrease in the rate of device-related 
complications and better clinical outcomes, including survival time on support [2, 3]. 
LVADs can be employed either as a bridge to heart transplantation (BTT) or as a 
destination therapy (DT) in patients who are ineligible to transplant. LVADs represent 
the vast majority of the employed long-term Mechanical Circulatory Support (MCS) 
devices [4], over biventricular support strategies and pulsatile devices. Nonetheless, 
LVAD therapy remains associated with significant rates of major morbidity, both 
immediate and in the long-term follow-up. These include mainly driveline and pump 
pocket infection, right ventricular failure, thromboembolic and hemorrhagic events, 
pump thrombosis, and rhythm disturbances [5]. A number of these complications 
have been associated with suboptimal LVAD implantation and positioning of LVAD 
components with respect to the cardiac structures [6]. 
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   The implantation procedure of LVADs has been based so far on general 
anatomical principles and surgeon’s adaptation to the individual anatomical 
characteristics, on the basis of clinical common sense. Similarly, the pathophysiology 
of many cases of pump thrombosis and thromboembolic events during LVAD support 
remains unknown [4, 7]. These complications represent a growing problem during the 
recent years [8]. The quality of apical cannula position, the occurrence of stasis and 
turbulent blood flow within the LV cavity as well as within the aortic root represent 
major determinants of thrombotic events [6, 7]. Currently, we are missing tools to 
further improve the positioning of LVAD devices in a patient-specific fashion.    
    
 
The Hypothesis 
   We postulated that: 
1. In patients presenting selected complications under LVAD support (i.e. 
thromboembolic events, pump thrombosis, severe rhythm disturbances, 
ineffective LV drainage, etc.), the analysis of the implanted LVAD through 
segmentation and three-dimensional reconstruction of the patients’ CT scan 
may provide patient-specific insights into the pathophysiology of the 
complication. Therapeutic interventions (i.e. adaptation of the anticoagulant 
therapy) could be prompted as a consequence. 
2. In candidates to LVAD treatment, preoperative virtual implantation and 
subsequent computer-assisted surgery might enhance the implantation of 
LVAD in a patient-specific fashion. Optimization of LVAD function and 
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decrease in the rate of both immediate and long-term complications are 
expected.  
 
Evaluation of the Hypothesis 
   For the preliminary testing of the hypothesis, we assembled a dedicated research 
team combining heart failure surgeons (AA and EF), biomedical engineers (SC) and 
an expert in medical image processing for innovative clinical applications (PH) [9]. 
We retrospectively selected patients who received LVAD implantation at a single 
University cardiac surgery center, and who had undergone contrast-enhanced chest 
CT scan during the follow-up. The indication to LVAD therapy was decided by 
multidisciplinary consensus of heart failure cardiologist and cardiac surgeons, 
according to the current recommendations [10]. CT scans had to be performed with a 
slice thickness ?1.25 mm with contrast injection of both ventricles and atria; they had 
to present limited noise and artifacts due to other endovascular devices (i.e., 
pacemaker and internal automatic defibrillator leads, although the presence of any of 
these devices did not constitute an exclusion criterion) and sufficient visibility of the 
mitral valve leaflets and annulus (grey values calibrated on the Hounsfield scale). 
According to these criteria, among 47 consecutive patients who received LVAD 
implantation at our center during the 2008-2014 period, we retrospectively selected 
14 individuals (BTT in 9 cases and DT in 5 cases) having postoperative CT scan 
complying with the above requirements. CT scan investigations were performed 
during the follow-up on the basis of various indications (such as exploration of 
driveline infection and ruling out of intracavitary thrombus). The implanted LVAD was 
the Thoratec HeartMate II in 10 instances (Thoratec Corporation, Pleasanton, CA), 
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the Jarvik2000 Flowmaker in 3 cases (Jarvik Heart Inc., New York, NY), and the 
HVAS in one (Heartware Inc., Framingham, MA). CT scans were elaborated in order 
to achieve a three-dimensional reconstruction of the whole heart, of the LVAD and of 
the thoracic wall (osseous components) through semi-automatic segmentation 
method (ITK-Snap software, Philadelphia, PA).  
   The postoperative analysis of device positioning was based on the principles of the 
state-of-the-art implantation, as recommended by the consensus of LVAD surgeons 
and manufacturers’ instructions [6]. The intraventricular inflow cannula needs to be 
coaxial with the mitral valve orifice and parallel to the interventricular septum, in order 
to optimize blood drainage and avoid conflict of the cannula with the endocardial 
surface. This may lead to obstructed flow, suboptimal device functioning, ventricular 
arrhythmias and potentially to thromboembolic events due to blood stasis and 
turbulences. In order to calculate the coaxiality with the mitral valve orifice, users 
(LVAD surgeons) were asked to define on postoperative CT scan slices a series of 
points (between 15 and 20) corresponding to the contour of the mitral annulus (3D 
Slicer Software [11]). The interface subsequently provides the average plane of the 
mitral valvular orifice and the center of the orifice (Figure 2A). A coordinate system 
was defined in order to quantify the coaxiality of the implanted LVAD’s apical cannula 
with this plane. Briefly, the latero-lateral axis (x) is defined by the center of the orifice 
and the annular point corresponding to the anterior mitral commissure, and the 
anterior-posterior axis (y) is defined as the perpendicular to the latero-lateral axis on 
the mitral plane. The third axis (z) is defined as the perpendicular to the mitral plane 
at its center. Subsequently, the axis of the LVAD apical cannula is obtained from the 
representation of the implanted device from semi-automatic segmentation. The axis 
of the apical cannula is described with respect to the mitral valve coordinates system 
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according to two angles: ϕ (representing the orientation of the LVAD cannula with 
respect to the anterior or inferior LV wall) and θ (representing the orientation of the 
LVAD cannula towards either the lateral LV wall or the interventricular septum - IVS) 
(Figure 2B). These angles provide the rotation coordinates of the LVAD apical 
cannula with respect to the mitral valve orifice. Ideal values are ϕ=0° and θ=0°. For 
the θ angle, values >0° and <0° indicate displacement towards the anterior or inferior 
LV wall, respectively. For the ϕ angle, values >0° and <0° indicate displacement 
towards the lateral LV wall or the IVS, respectively. Angles ϕ and θ were calculated 
for the 8 patients included in this preliminary study; values could be also expressed 
as percent variation with respect to the ideal value. This percentage is expressed 
with a based number of 90° (ϕ=0° represents a variation of 0%, ϕ=+90° or ϕ=-90° 
represent a variation of 100%).  
   The patients’ clinical records were reviewed in order to identify early postoperative 
and late complications which could be ascribed to suboptimal device positioning. 
Among these, we included thrombotic and thromboembolic events (pump thrombosis, 
LV cavity thrombus, stroke, transient ischemic attack – TIA, suboptimal pump flow 
and persisting suction events despite intravascular volume expansion, severe early 
ventricular arrhythmias after LVAD implantation in patients without preoperative 
history of severe arrhythmia). Suction events are characterized by iterative, abrupt 
drops in pump flow due to impingement of the apical cannula orifice with the 
endocardial surface (typically, the IVS). Severe repeated ventricular arrhythmias 
immediately after LVAD implantation can be ascribed to inappropriate stimulation of 
the endocardial surface from a misplaced cannula. Hemorrhagic stroke was not 
considered as a complication endpoint with respect to the present investigation, 
similar to other issues such as noncerebral hemorrhagic events and driveline/pump 
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pocket infection. These were considered to be scientifically unrelated with the 
purposes of this study. We stratified the patients according to the history of at least 
one of these events within either the Complicated (Group 1) or Uncomplicated 
(Group 2) subgroup. Adverse events on LVAD support were defined according to 
current multi-Institutional registries [12].  
 
Analysis and data management.    
   Data were included prospectively into an electronic database. Average deviation of 
apical cannula axis with respect to the ideal value was described as mean ± standard 
deviation (continuous data). Categorical data were presented as percentages. 
Continuous data were compared using the two-tailed Student’s t test. The 
Kolgoromov-Smirnoff test was employed to verify normality of distribution. The alpha 
value was 0.05; analyses were performed through the SPSS software ver. 19.0 for 
Windows (SPSS, Chicago, IL). Sample size calculation was conducted using the PS 
software ver. 3.0 for Windows.  
   The present retrospective study did not entail any additional diagnostic or 
therapeutic protocol than current clinical management, and all data were managed 
anonymously.  
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Empirical data 
   The segmentation of the whole heart and of the implanted LVAD could be 
successfully performed for all of the selected patients. Table 1 summarizes the 
results of the analysis of apical cannula axis positioning with respect to the mitral 
annular plane, stratified among complicated vs. uncomplicated patients. Seven 
patients (50% of the present population) were included in the Complicated subgroup 
(Group 1) and the remainders entered the Uncomplicated subgroup (Group 2). 
Complications were thromboembolic events (stroke and TIA) in four cases, pump 
thrombosis in one case and device malfunction (device failure and early severe 
ventricular arrhythmias) in two cases. Average duration of postoperative follow-up 
was 24.9 months ± 16.1 and 29.4 months ± 13.7 in the Complicated and 
Uncomplicated Group, respectively (p=0.53). In Group 1, all but two patients 
presented rotation of the apical cannula towards the interventricular septum (IVS). 
For these two cases, percent rotation towards the left ventricular lateral free wall was 
minimal (average: 4.4%). Average percent rotation of the apical cannula towards the 
IVS was 55.1% ± 31.8 in Group 1, and 13% ± 12.1 in Group 2 (p=0.015). Average 
percent rotation of the apical cannula towards the inferior or anterior LV wall was 
36% ± 26.4 in Group 1, and 46.8% ± 28.8 in Group 2 (p=0.48).  
   Reconstruction and morphological examination of CT scans of LVAD recipients 
suggested the role of device contact with the thoracic wall (closed chest conditions) 
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in determining device and cannula displacement with respect to the target position 
(Figure 3A and 3B). 
   A sample size calculation suggested that a total of 154 patients should be enrolled 
to one among two alternative strategies (with or without postoperative analysis of 
device positioning and consequent management of anticoagulant treatment) to detect 
with a 80% power and a 0.05 alpha level a significant 50% reduction in the rate of 
thromboembolic events during a 3-years follow-up. This sample size calculation will 
need to be refined through data from additional preliminary investigations.  
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Consequences of the Hypothesis 
   Landmark randomized studies have demonstrated that LVAD implantation is 
associated with better survival than medical treatment in patients with end-stage 
heart failure who are not candidates to heart transplantation (REMATCH Study) [13]. 
LVAD implantation also allows improved functional capacities and provides a better 
quality of life to these patients [14, 15]. Currently, around 4,000 new patients are 
enrolled every year in the international INTERMACS registry after having received an 
LVAD [4]. Moreover, the proportion of patients receiving LVAD as DT is constantly 
increasing over BTT patients; this amplifies the need to further reduce the 
complications rate under support for patients who cannot benefit of heart transplant 
in case of LVAD-related issues. The occurrence of complications during LVAD 
support (namely, thrombotic and embolic events) is multifactorial, and proceeds from 
the interaction of multiple patient- and device-related elements. Mechanical and non-
mechanical factors (including suboptimal anticoagulant therapy and proinflammatory 
conditions) can be involved in the pathophysiology of thrombotic events. The present 
work is specifically addressed at the prevention of mechanical causes through 
improved implantation of LVADs. There is a link between suboptimal device 
implantation and pump thrombosis or thromboembolic events [16, 17]. It has been 
suggested that the inflow cannula of an HeartMate II LVAD should present an angle 
of approximately 15°-30° with respect to the patient’s vertical axis and of 75°-60° 
relative to the pump body on anteroposterior chest X-rays. The apical cannula should 
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also be parallel to the IVS [6]. The site of apical LV coring plays a major role in the 
determinism of cannula orientation. Nonetheless, the rate of stroke under LVAD 
support remains considerable despite accurate surgical technique. Although the rate 
of thrombotic and thromboembolic complications on LVAD support is relatively 
contained, their occurrence is associated with major morbidity/mortality and loss of 
quality of life. Therefore, their prevention is among the main concerns of LVAD 
teams. 
   We hypothesized that more refined analysis of pump positioning is required to 
better understand the propensity to thrombosis and suboptimal device function in 
individual patients, and that the implantation technique can be further improved and 
customized through preoperative virtual implantation and computer-assisted surgery. 
Such hypothesis is supported not only by previous literature and clinical experience, 
but also by the present original data suggesting that less proper intraventricular 
cannula orientation is associated with occurrence of early and late complications. In 
particular, Group 1 patients showed significantly greater percent improper cannula 
rotation towards the IVS (p=0.015). In the present limited series, we did not observe 
a significant difference in terms of average percent θ rotation among subgroups. 
Nonetheless, average ϕ rotation towards the IVS was significantly different among 
the complicated vs. uncomplicated patients groups, and it may become a useful 
indicator when markedly oriented towards the IVS. Given the present data, we will 
expand the dataset through performance of dedicated CT scan of additional patients 
in order to gather additional information on these issues. Although the presence of 
intracavitary defibrillator and pacemaker leads may generate artifacts, this only 
occasionally compromises the exploitability of CT-scan images with the purposes of 
3D reconstruction and device positioning analysis. Future developments will involve 
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the inclusion of flow simulation within reconstructed LV cavities of patients under 
LVAD. Several previous works employing numerical hemodynamic simulation have 
suggested a link between the morphology of the LV cavity, the position of the LVAD 
inflow cannula and the development of flow patterns predisposing to thrombus 
formation [18, 19, 20]. Nonetheless, no clinical application has been attempted until 
now.  
   During current state-of-the-art LVAD implantation, the surgeon identifies the LV wall 
coring zone within a region at the LV apex lateral to the left anterior descending 
artery, under transesophageal echocardiography guidance to try achieving coaxiality 
with the mitral valve orifice. Such protocol remains essentially qualitative and 
exposes to the risk to disregard individual anatomical features with potential impact 
on final placement of the apical cannula. In fact, LVAD recipients present a vast array 
of underlying etiologies (primary dilated cardiomyopathy, ischemic heart disease, 
hypertrophic cardiomyopathy…) with variable degrees of symmetric or asymmetric 
LV dilatation and different morphologies of the LV cavity [4]. This determines an 
extreme variability in intracavitary geometrical and flow conditions after LVAD 
implantation.  Additionally, since LVADs are implanted through full median 
sternotomy in the vast majority of instances, it is difficult for the operating surgeon to 
anticipate the interaction between the chest wall and the device after chest closure. 
Implantation of the LVAD cannula demands luxation of the LV apex and distortion of 
the normal anatomical relations. This adds another factor of variability with respect to 
the choice of the cannulation site and the final positioning of the LVAD device within 
the chest. Device conflict with the rigid chest wall may alter the apical cannula 
orientation at the end of surgery. Until now, the latter aspect has been investigated in 
the field of total artificial heart implantation [21]. Herein, original analysis of the 
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interaction between the closed chest wall and the implanted device (Figure 3) 
provides one potential explanation for postoperative device migration [6], as well as 
one further variable to be considered in the computer-assisted planning of LVAD 
implantation. 
   Computer-assisted surgery is a complex discipline integrating various technologies 
and sources of data, such as pre- and intraoperative imaging, virtual reality, 
augmented reality, interactive simulation and micro-technologies [9, 22]. The major 
fields of application have been neurosurgery and orthopedic surgery [23, 24, 25], 
although innovative applications are being proposed in endovascular surgery [26]. 
The present preliminary work in the field of surgery for advanced heart failure opens 
new avenues of potential applications, including preoperative planning of optimal 
LVAD positioning (i.e., epicardial coring site which allows the best possible alignment 
with the mitral valve and less generation of intracavitary turbulent flow patterns, 
taking into account the geometrical limitations imposed by the chest wall).  
   Henceforth, we started the development of a tool for preoperative virtual 
implantation for intended future clinical use. Segmentation and reconstructed cardiac 
volumes were managed through a computer interface (Figure 4A). In such interface, 
the reconstructed cardiac structures can be scrolled within a 3D slice view 
corresponding to the representation of the coronal, transversal and sagittal CT scan 
slices. Parallel to cardiac chamber segmentation, we constructed a three-dimensional 
mesh component representation of two commercially available LVADs (ITK-Snap 
software, Philadelphia, PA). The Thoratec HeartMate II and the HeartWare HVAS 
were employed. To such purpose, we used rotational imaging of the LVADs (cone-
beam computed tomography) in order to minimize artifacts (Figure 4B). The mesh 
representation of LVADs can be integrated within the same interface in order to allow 
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real-time spatial manipulation by the user and virtual implantation within the CT scan 
volumes (Figure 4C). Our ultimate purpose is to provide a user-friendly software for 
interactive simulation and procedural planning, which could be employed by 
surgeons and cardiologists. Other software are currently used clinically for, in 
example, sizing transcatheter heart valves and aortic endoprostheses. Such 
developments proceed from the hypothesis illustrated herein and from the above 
empirical data. These developments are still at an early stage; nevertheless, 
verification of the hypothesis through analysis of further postoperative CT-scans will 
be required. 
   There are several limitations to the present investigations, including the limited 
number of patients contributing to the empirical data, and the purely morphological 
approach employed so far in the analysis of implanted patients. Despite these 
limitations, we can hypothesize that the current clinical results of LVAD treatment can 
be optimized through preoperative computer-assisted simulation of device 
implantation. In patients who have been already implanted, screening through CT 
scan and apical cannula position analysis (coupled with intracavitary flow pattern 
simulation) may help in the future to stratify the propensity to develop 
thromboembolic complications and guide preventive intervention (adaptation of the 
anticoagulant therapy and addition of long-term antiplatelet treatment). Such 
hypothesis is supported by original data. Residual LV volume around the inflow 
cannula and its distance from the mitral valve plane will also be investigated for 
relationship with adverse events. Additionally, the morphology of the inflow cannula 
varies among the commercially available LVADs. This will need to be taken into 
account into future studies, through achievement of sufficient sample size to stratify 
the results according to devices, and through analysis of the hemodynamic effects of 
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various cannula morphologies. On these bases, we are going to initiate a prospective 
study in larger patient subsets to validate such hypothesis. Multicentre cooperation 
will be probably necessary at more advanced research stages in order to clinically 
demonstrate a reduction in thromboembolic rate. Preoperative virtual implantation 
and subsequent computer-assisted surgery strategies may be employed in the future 
to achieve a greater and customized level or precision and reproducibility in LVAD 
implantation.  
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Figure Legends 
Figure 1. Representation of a Thoratec HeartMate II LVAD.  
Figure 2.  Analysis of apical LVAD inflow cannula position with respect to the target 
mitral valve orifice (green disks).  A. The mitral valve plane is defined semi-
automatically by the user.  B. Coordinates system to describe the orientation angles 
(ϕ and θ).     
Figure 3.  Analysis of LVAD interaction with the thoracic wall in closed chest 
conditions.  A. Reconstruction of post-implantation CT scan showing anterior 
displacement of the intraventricular inflow cannula.  B. Addition of the chest wall 
structure reconstruction in the same patient showing thoracic collision and 
consequent posterior orientation of the pump body. 
Figure 4. Development of an interactive interface for CT scan navigation, 
segmentation of cardiac chambers and manipulation of LVAD component mesh. A. 
Cardiac volumes segmentation.  B. Component mesh representation of a HeartMate 
II LVAD. Nc is the vector representing the inflow cannula axis.  C. Example of spatial 
manipulation of the LVAD component mesh by the user within the 3D environment.   
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Table 1. Analysis of positioning of LVAD apical cannula with respect to the mitral 
valve plane. Group 1 and 2 are the Complicated and Uncomplicated subgroups, 
respectively. IVS: Interventricular septum. See the text for definitions. *Modified 
interpretation of angles due to adaptation of the coordinate system to the anatomy of 
this particular case.  
 
Patient  
 
Orientation (°) 
 
P4 (Group 1) 
 
θ = -41.17 (45.7% inferior) 
ϕ = -82.54 (91.7% towards IVS) 
 
P10 (Group 1) 
 
θ = 72.40 (80.4% anterior) 
ϕ = -35.98 (40% towards IVS) 
 
P14* (Group 1) 
 
θ = 78.48 (87.2% towards IVS) 
ϕ = 24.04 (26.7% anterior) 
 
P16 (Group 1) 
 
θ = 51.78 (57.5% anterior) 
ϕ = 6.86 (7.63% lateral) 
 
P17 (Group 1) 
 
θ = 9.66 (10.7% anterior) 
ϕ = -27.6 (30.7% towards IVS) 
 
PJ3 (Group 1) 
 
θ = -19.2 (21.3% inferior) 
ϕ = 1.02 (1.13% lateral) 
 
PW1 (Group 1) 
 
θ = 51.78 (57.5% anterior) 
ϕ = 6.86 (7.63% lateral) 
 
P3 (Group 2) 
 
θ = -8.62 (9.58% inferior) 
ϕ = -23.36 (25.9% towards IVS) 
 
P5 (Group 2) 
 
θ = 37.47 (41.6% anterior) 
ϕ = -9.74 (10.8% towards IVS) 
 
P9 (Group 2) 
 
θ = 53.76 (59.7% anterior) 
ϕ = -2.36 (2.6% towards IVS) 
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P13 (Group 2) 
 
θ = 82.56 (91.7% anterior) 
ϕ = -32.09 (35.6% towards IVS) 
 
P15 (Group 2) 
 
 
θ = 51.7 (57.4% anterior) 
ϕ = -13.54 (15% towards IVS) 
 
PJ1 (Group 2) 
 
θ = -12.02 (13.4% inferior) 
ϕ = 1.49 (1.66% lateral) 
 
PJ2 (Group 2) 
 
θ = 7.89 (8.8% anterior) 
ϕ = -2.54 (2.82% towards IVS) 
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